The present invention concerns a composition comprising vesicles and encapsulated within the vesicles, an antibody, wherein the vesicles comprise an amphiphilic block copolymer having a hydrophilic and a hydrophobic block. Methods of delivering the above compositions into cells are also described.

Described are amphiphilic polymers that are provided with chelating moieties. The amphiphilic polymers are block copolymers comprising a hydrophilic block and a hydrophobic block, with the chelating moieties linked to the end-group of the hydrophilic block. The disclosed polymers are capable of self-assembly into structures such as micelles and polymersomes. With suitable metals present in the form of coordination complexes with the chelating moieties, the chelating amphiphilic polymers of the invention are suitable for use in various imaging techniques requiring metal labeling, such as MRI (T.sub.1/T.sub.2 weighted contrast agents or CEST contrast agents) SPECT, PET or Spectral CT.

The present invention provides methods for delivery of therapeutic agents to a subject using multi-component liposomal systems. The methods include administration of a therapeutic liposome containing an active agent, followed by a administration of an attacking liposome that induces release of the agents from the therapeutic liposome.

Methods for preparation of novel amphiphilic derivatives of thioether containing block copolypeptides with narrow chain length distributions are described. These block copolymers can be chemically modified by oxidation and alkylation of the thioether containing residues. These materials generate self-assembled micelles, vesicles and hydrogels, or emulsions with oil phases. These assemblies can be used to encapsulate and delivery therapeutic molecules. The assemblies can be taken up by cells to release molecules from the assemblies.

Lipidic compound (lipidic molecule)-telodendrimer hybrid nanoparticles. For example, the lipidic compound-telodendrimer hybrid nanoparticles are lipid/lipidoid-telodendrimer hybrid nanoparticles. The nanoparticles can comprise a plurality of lipidic molecules (e.g., lipid molecules, lipidoid molecules, or mixtures of different lipid molecules or different lipidoid molecules). The hybrid nanoparticles can comprise one or more lipid or lipidoid and one or more telodendrimer. The hybrid nanoparticles can also comprise cholesterol. In various examples, the hybrid nanoparticles also comprise a small molecule, peptide, protein, or a combination thereof. In various examples, lipid-telodendrimer hybrid nanoparticles comprising one or more small molecules or lipidoid-telodendrimer hybrid nanoparticles comprising one or more protein(s) and/or peptide(s) are used in methods of small-molecule or protein/peptide delivery.

Provided are co-assembled nanoparticles including at least one polypeptide including a polyanion; and at least one amphiphilic peptide capable of forming a β-sheet structure, a derivative or a salt thereof, the amphiphilic peptide including at least 2 pairs of alternating hydrophobic/hydrophilic amino acid residues in which the hydrophilic amino acid residue is positively charged, and methods of preparation of the nanoparticles. Further provided are pharmaceutical compositions including the co-assembled nanoparticles and a pharmaceutically active ingredient, dissolved, entrapped, encapsulated or attached to the co-assembled nanoparticles. Further provided are therapeutic uses of the pharmaceutical compositions.

A polymeric compound is disclosed herein, having the general formula I: ##STR00001##
wherein m, n, X, Y, Z and L are as defined herein. Further disclosed herein are lipid bilayers comprising at least one bilayer-forming lipid and the aforementioned polymeric compound, and liposomes comprising such a bilayer, as well as methods, uses and compositions utilizing such bilayers and/or liposomes for reducing a friction coefficient of a surface and/or for inhibiting biofilm formation.

Stimuli-responsive NPs with excellent stability, high loading efficiency, encapsulation of multiple agents, targeting to certain cells, tissues or organs of the body, can be used as delivery tools. These NPs contain a hydrophobic inner core and hydrophilic outer shell, which endows them with high stability and the ability to load therapeutic agents with high encapsulation efficiency. The NPs are preferably formed from amphiphilic stimulus-responsive polymers or a mixture of amphiphilic and hydrophobic polymers or compounds, at least one type of which is stimuli-responsive. These NPs can be made so that their cargo is released primarily within target certain cells, tissues or organs of the body, upon exposure to endogenous or exogenous stimuli. The rate of release can be controlled so that it may be a burst, sustained, delayed, or a combination thereof. The NPs have utility as research tools or for clinical applications including diagnostics, therapeutics, or combination of both.

A telodendrimer-nanolipoprotein particle (t-NLP), comprising one or more membrane forming lipids, one or more telodendrimers, and a scaffold protein and a Chlamydia major outer membrane protein (MOMP) comprising a MOMP hydrophobic region, and related compositions methods and systems.

An amphiphilic block copolymer having any one of the formulas S-[B]-H, S-[B]-H(D), D-[B]-H, S-B(D)-H, S-[B]-H-[B]-S, S-[B]-H(D)-[B]-S, D-[B]-H-[B]-S, D-[B]-H-[B]-D, S-B(D)-H-[B]-S or S-B(D)-H-B(D)-S; wherein S is a hydrophilic surface stabilizing group; B is a spacer group; H is a hydrophobic polymer or oligomer; D is a drug molecule; ( ) denotes that the group is bonded directly or indirectly as a side chain or as part of a side chain group to the adjacent group; [ ] denotes that the group is optional; and - denotes that each of the adjacent S, B, H or D are linked directly to one another or indirectly to one another via a linker group.